REGULATORY
    CEA Use in Reimbursement Decisions Our Ultimate Goal: MOF Budget Examiner
    By Yoshinori Sagehashi April 19, 2019
    Japan is to not use its new cost-effectiveness assessment (CEA) scheme for reimbursement decisions - at least for now - but this would give no respite for the industry as budget examiner Iichiro Yoshino says…

    LATEST

    Novartis to Begin Kymriah Treatment at 2-3 Japan Sites, Looks at Gradual Expansion
    April 19, 2019
    Novartis Pharma expects “around two to three” institutions in Japan to initially provide its CAR-T cell therapy Kymriah (tisagenlecleucel), but it hopes to gradually increase the number of certified sites that can offer the treatment with the highest standards, Japan…
    Boehringer to Remain Major Employer in Japan with As-Needed Staffer Placement
    April 19, 2019
    Despite its recent downsizing in Japan, Boehringer Ingelheim will remain “a major employer” in the country by deploying staffers where and when necessary in keeping with changes in its local portfolio, the company’s global pharma…
    Number of Contract Sales Reps Down 11.5% in FY2018: JCSOA
    April 19, 2019
    The number of contract sales reps in Japan fell by 11.5% compared to the previous year to 3,110 as of October 2018, the Japan Contract Sales Organization Association (JCSOA) said on April 17. Contract reps…

    Upside in Decelerating Gx Arena

    Nihon Generic to Mount Aggressive Sales Campaigns Taking Advantage of Group Synergy
    By Takashi Ebisawa and Tatsuya Otsuka

    Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…

    COMMENTARY

    Cell Therapy Makers Working to Stand Out from Rivals by Reducing Burdens on Hospitals
    By Takashi Ebisawa

    Manufacturers of regenerative medicine-based products are beginning to differentiate themselves from competitors based not only on efficacy but also on the reduction of burdens on medical institutions where their therapies are provided.The procedures required for administering regenerative medicine products are…

    My Viewpoint on CEA

    With 90% Premium Cut, Japanese CEA Scheme Goes Beyond Its Purpose of Being “Complementary” Tool: FPMAJ Pricing Chief
    By Yoshinori Sagehashi

    Japan positions its new cost-effectiveness assessment (CEA) scheme merely as a tool to complement the current drug pricing system, but…

    INTERVIEW

    I’ve Done Everything I Can in 11 Years, Says Outgoing PMDA Chief

    Tatsuya Kondo, chief executive of the Pharmaceuticals and Medical Devices Agency (PMDA), is hitting the exit at the end of…

    HTA Debates in 2018-2019

    Japan to Roll Out Cost-Effectiveness Assessment Scheme in April

    Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

    TRENDS

    Drug Makers on Hunt for “Mibyo” Biz Opportunities as Pricing Rules Get Stricter
    By Reiji Anasako

    With Japan’s tighter price control casting a chill over its pharma market, companies are setting their sights beyond the field of health insurance to carve out a new revenue stream, seeking opportunities in the business to tackle “mibyo” - a…

    NEWS CATEGORY

    REGULATORY

    BUSINESS

    ORGANIZATION

    ACADEMIA